as of 08-14-2026 3:34pm EST
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 61.8M | IPO Year: | 2000 |
| Target Price: | N/A | AVG Volume (30 days): | 316.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | -28.77 |
| 52 Week Low/High: | $0.86 - $2.03 | Next Earning Date: | 05-13-2026 |
| Revenue: | $41,119,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.50 | Index: | N/A |
| Free Cash Flow: | -32833000.0 | FCF Growth: | N/A |
See how FLNA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "FLNA Filana Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.